Jefferies Group’s Matinas BioPharma MTNB Stock Holding History

Jefferies Group’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-744	Closed	-$22K	–	1808
2020 Q1	$22K	Buy	+744	New	+$44.9K	﹤0.01%	1932

Other funds holding MTNB

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Jefferies Group's MTNB Position: Q2 2020 in Review

Jefferies Group sold out of Matinas BioPharma (MTNB) in Q2 2020, closing a stake of 744 shares — an estimated $22K sold.

Jefferies Group first reported a position in MTNB in Q1 2020 and held it in 1 quarter. The position peaked at $22K in Q1 2020. 65 funds tracked by Wall St. Rank hold MTNB as of Q2 2020.

Jefferies Group reported no remaining Matinas BioPharma position as of Q2 2020 after selling out during the quarter.
Jefferies Group sold 744 Matinas BioPharma shares in Q2 2020, an estimated $22K.
Jefferies Group first reported a position in Matinas BioPharma in Q1 2020 and held it in 1 quarter.
Jefferies Group's Matinas BioPharma position peaked at $22K in Q1 2020.
65 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2020.

Based on Jefferies Group's 13F filing for Q2 2020, filed 14 Aug 2020.